Innovative lipid-lowering therapy: personal experience of using Inclisiran

Prevention of cardiovascular diseases (CVD) is a priority area of modern medicine and healthcare. Dyslipidemia occupies a special place among traditional risk factors, the correction of which significantly improves the prognosis and reduces the risk of cardiovascular events. The modern paradigm of dyslipidemia correction involves the use of high-intensity statin therapy, and if they are ineffective, combined lipid-lowering therapy with the inclusion of innovative drugs that block the activity or production of a specific PCSK9 protein, the level of which affects the degradation of proatherogenic lipids. Currently, the arsenal of lipid-lowering drugs has been replenished with the drug inclisiran, which is a modified interfering RNA (mi-RNA) targeted at the PCSK9 messenger RNA. The results of clinical trials have proven the high efficacy and safety of inclisiran, as well as the possibility of its use in patients with poor tolerance.The article presents a clinical observation of the use of inclisiran as part of combined lipid-lowering therapy for secondary prevention in a comorbid patient with very high cardiovascular risk (CVD) and statin intolerance. It was shown that the intensification of lipid-lowering therapy with the help of inclisiran made it possible to quickly reduce the level of LDL-C (50 % of baseline) and avoid adverse events associated with taking statins.